Arthritis & rheumatology (Hoboken, N.J.)
Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study.
Rituximab versus cyclophosphamide for IgA vasculitis.
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.
Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis.
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis.
Differences in dynamics of specific anti-nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus.
Patterns of infliximab biosimilar uptake for Medicare, Medicaid, and private insurance from 2016-2022.
Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials.
The Hydroxychloroquine Conundrum: Striking the Right Balance Between Safety and Efficacy in Rheumatology Practice.
